Treosulfan and Fludarabine for Transplantation 
INTRODUCTION
For many years, conditioning therapy prior to allogeneic transplantation has been based on the combination of the alkylators busulfan and cyclophosphamide or total body irradiation (TBI) and cyclophosphamide. Stem cell toxicity to induce myeloablation, immunosuppression to improve engraftment/prevent rejection, and antineoplastic activity are the major goals of the supralethal doses of chemotherapy and radiation. With the introduction of new conditioning approaches such as non-myeloablative treatment 1 or mini-transplantation, 2 the perception of the aims of conditioning for certain indications has changed: conditioning now is necessary to provide a platform for the development of complete donor chimerism, and the graft-vs.-leukemia/lymphoma/tumor effect is considered to be more important for cure than the antineoplastic activity of the conditioning regimen itself. Therefore, severe mucositis and leukopenia are no longer unavoidable in the early posttransplantation period, when doses of conditioning therapy are significantly reduced. However, other side effects such as venoocclusive disease (VOD) induced by busulfan 1, 3-5 may not be excluded even after reducedintensity conditioning. In addition, with the use of "new" drugs like melphalan, adverse events that were not normally associated with these drugs, such as cardiotoxicity, have been reported. 6, 7 Therefore, the introduction of alternative conditioning agents such as treosulfan may further improve the therapeutic options in allogeneic transplantation.
Treosulfan (L-threitol-1,4-bis-methanesulfonate; dihydroxybusulfan; NSC 39069; Ovastat ® ) is a prodrug of a bifunctional alkylating cytotoxic agent that is approved for the treatment of ovarian carcinomas in a number of European countries. 8, 9 Hematotoxicity is dose limiting in conventional therapy. 10 Only recently, in two Phase I protocols with autologous blood stem cell rescue, was it possible to escalate the dose to almost five times the maximum tolerated dose defined by conventional therapy before mucositis/stomatitis, diarrhea, skin toxicity, and acidosis became dose limiting. 11, 12 In vitro data confirm the pronounced effect of treosulfan against primitive hematopoietic stem cells, 13 and repeated dosing of treosulfan is at
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From least as effective as busulfan or TBI in inducing reliable donor-cell engraftment in mice. 14 , 15 The antitumor activity of treosulfan has been shown in a variety of solid tumors. [16] [17] [18] [19] In myeloma and in chronic and acute myelogenous leukemia, treosulfan is a potent inducer of cell death, being equal or even superior to melphalan or busulfan. Both epoxide species are supposed to be responsible for DNA alkylation, interstrand crosslinks, chromosomal aberration, and induction of apoptosis. 26, 27 Because of its limited nonhematologic (organ) toxicity, treosulfan may therefore offer a promising alternative to conventional conditioning agents in the setting of toxicity-reduced allogeneic transplantation.
Fludarabine has already been incorporated into a number of non-myeloablative or reduced-intensity conditioning regimens. 1, 28, 29 Fludarabine is known to inhibit DNA repair. 30 Besides its activity against lymphoid neoplasms, 31 its favorable toxicity profile and assumed immunosuppressive characteristics were the reasons for its introduction into several conditioning regimens. 1 In the current Phase I/II study, treosulfan and fludarabine were used as the preparative regimen before allogeneic transplantation, combining the effects of DNA damage caused by treosulfan with inhibition of repair by fludarabine. The treosulfan dose of 30 g/m² (three times the maximum tolerated dose of conventionally dosed treosulfan) was chosen in order to ensure sufficient stem cell toxicity and antineoplastic efficacy and at the same time to avoid serious non-hematologic toxicity.
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PATIENTS, MATERIALS, AND METHODS

Patient Eligibility
Patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), or chronic lymphocytic leukemia (CLL) who were between the ages of 18 and 65 years and at unacceptable risk for conventional conditioning were enrolled by three German transplantation centers. The first five patients were treated in a pilot phase according to the protocol, which was approved by the ethics committee thereafter. All patients gave written informed consent. The characteristics of the patients and the risk factors for conventional conditioning are listed in Table 1 . Patients were required to have an HLA-identical family or unrelated donor, as determined by serologic typing for HLA A/B and molecular typing for HLA DRB1.
Conditioning Regimen
Patients received fludarabine 30 mg/m² intravenously each day over 30 minutes from day -6 to day -2 and treosulfan 10 g/m² intravenously over 2 hours daily from day -6 to day -4. For patients with unrelated donors, rabbit antithymocyte globulin (Fresenius) 10 mg/kg was given intravenously daily from day -4 to day -2.
Supportive Care
Patients were managed in laminar airflow rooms. All patients received prophylactic cotrimoxazole against Pneumocystis carinii infection. Acyclovir and fluconazole or itraconazole prophylaxis was routinely used. Red cell and platelet transfusions were given to maintain hemoglobin levels above 8 g/dL and platelet counts above 20 × 10 9 /L. Blood products were irradiated. Neutropenic patients received broad-spectrum antibiotics according to each hospital's policy for the management of febrile neutropenia.
Filgrastim at 5 µg/kg per day was administered intravenously or subcutaneously from day 1 until the leukocyte count had been at least 1.0 × 10 9 /L for 3 consecutive days.
Prophylaxis for GVHD consisted of two doses of cyclosporine A (CSA) 1.5 mg/kg every 12 hours starting on day -1. CSA was administered intravenously until discharge and continued afterwards as oral medication. Doses were adjusted to maintain whole-blood steady-state trough concentrations between 200 ng/mL and 250 ng/mL and modified as clinically indicated for nephrotoxicity. The CSA was administered at full dose through day 42. Thereafter, if GVHD did not occur, the protocol allowed a tapering of the CSA dose by 10% every week.
Chimerism Analysis
Chimerism was evaluated using PCR to amplify microsatellites. Genomic DNA was prepared from blood and bone marrow using the QIAamp DNA Blood Mini Kit (Qiagen). 
Adoptive Immunotherapy
Patients who showed incomplete hematopoietic donor-type chimerism on or after day 28 or had evidence of relapse or disease progression were candidates for adoptive immunotherapy.
In patients still on immunosuppressive therapy but without signs of GVHD, immunosuppression was reduced. In patients with nonetheless persisting incomplete hematopoietic donor-type chimerism or increasing proportions of recipient cells, the immunosuppression was terminated. Patients without any concurrent immunosuppression and no signs of GVHD were candidates for donor lymphocyte infusion (DLI).
Statistical Methods
The two-sample exact Wilcoxon Mann-Whitney test was used to identify any significant difference in the distribution of GVHD with respect to the donor type (related or unrelated).
Actuarial curves and survival rates were estimated by the Kaplan-Meier method. Overall survival was measured from transplantation until death from any cause. Event-free survival was measured from transplantation until graft failure, progression, relapse, or death from any cause. Treatment-related mortality was determined from the date of transplantation until death related to transplantation. Patients who died from other causes were censored at the time of death. Toxicity was evaluated according to the Cancer Therapy Evaluation Program Common Toxicity Criteria, version 2.0, of the U.S. National Cancer Institute. Table 1) .
Engraftment and Chimerism
Twenty-nine patients (97%) had primary engraftment, as defined by leukocyte counts above 1.0 × 10 9 /L and platelet counts above 50 × 10 9 /L without transfusion for at least 3 consecutive days. The median leukocyte nadir (median 0.5 × 10 9 /L; range 0.03-59 × 10 9 /L) occurred at day 7. In 17 patients with a normal platelet count at the beginning of the conditioning the median time to platelet transfusion dependency -defined as the first day with platelets below 20 × 10 9 /L or substitution of platelet concentrates -occurred by day 7. Eight patients were transfusion dependent, and 5 patients already had decreased platelet counts at the beginning of the conditioning. Overall, leukocytes recovered to >1.0 × 10 9 /L at a median of day 10 (range day 4-19), neutrophils reached 0.5 × 10 9 /L at a median of day 11.5 (range day 6-19), and platelets exceeded 50 × 10 9 /L by a median of day 18 (range day 9-35).
Complete donor chimerism, defined as more than 95% donor cells in the bone marrow, was reached on day 14 by 70% (16/23) of the patients evaluated and on day 28 by 81% (22/27). In addition, two patients had complete donor chimerism when first tested on day 56, and one patient had reached complete chimerism by day 56. In a patient with CML (no. One patient (no. 17) died of septic shock on day 29 before an evaluation of donor chimerism was possible.
Toxicity and Non-relapse Mortality
As shown in Table 2 , the conditioning regimen with treosulfan and fludarabine was well tolerated. Acute nausea and vomiting reached CTC Grade 3 in only one patient and did not represent a clinical problem when patients were given 5HT 3 antagonists and dexamethasone.
Patients were able to eat at all times after conditioning. Mucositis did not exceed CTC Grade 
Acute and Chronic GVHD
All patients were evaluated for acute GVHD (aGVHD; Table 3 ). Of these, 43% (13/30) remained without signs of aGVHD, 27% had Grade I disease, and 17% had Grade II aGVHD.
There was a lower incidence in the patients receiving grafts from a matched related donor Twenty-six patients were evaluable for chronic GVHD (cGVHD). Limited cGVHD was found in two patients (8%) and extensive cGVHD in eight (31%). There were no major differences between the donor types and the occurrence or extent of cGVHD. The DLI induced GVHD in two patients.
Disease Response and Relapse
Disease status and transplantation outcome are shown in detail in Table 1 One patient (no. 26) with a diffuse large-cell NHL relapsed on day 113 and died of his disease on day 371. One patient (no. 24) with a T-cell NHL died on day 87 secondary to infection without any signs of disease progression.
Survival Analysis
Eight patients have died after transplantation, six (20%) of non-relapse-related causes and two (6.7%) of relapse on day 186 (AML) and day 371 (NHL). Thus, the estimated overall survival rate is 73% and the event-free survival rate 49% after a median follow-up of 22 months (range 7.4-33.4 months) (Fig. 1) . Taking into account that the success of a less-toxic conditioning regimen is in part related to a graft-vs.-malignancy effect after transplantation, reduction of the immunosuppression or DLI resulted in a current survival rate in complete remission of 63%.
There were no treatment-related deaths by day 28. By day 100, the treatment-related mortality reached 7% and did not exceed 17% by 1 year or thereafter. In the evaluation of treatment-related mortality, the patient (no. 8) suffering from sudden cardiac arrest secondary to severe accompanying amyloidosis was censored at the time of death (day 62) (Fig. 2) . For Considering the selection of poor-risk patients for this study, the treatment-related mortality rate of 17% compares favorably with that of reduced-intensity approaches. 34, 35, 37 -39 Despite the low non-hematologic toxicity, the combination of treosulfan and fludarabine may provide a rather high antineoplastic activity. Six of the seven patients with AML had a high relapse risk (transplant in second or later CR, first or second PR, or relapse), and only two patients suffered from relapse. No relapses were seen in the MDS or follicular center lymphoma patients, and none of five patients with multiple myeloma (four in the first through the fourth PR or with progressive disease) relapsed or progressed. This first impression is supported by the in vitro data of the antineoplastic activity of treosulfan in multiple myeloma 20 but has to be confirmed in a larger patient population with these diseases.
The rate of molecular or cytogenetic relapse in CML will have to be followed closely in the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From future; however, it has to be taken into account that these patients had long histories of disease or advanced CML. An additive effect of imatinib and treosulfan has been described in vitro and may be a subject for further investigations. In addition, the rate of primary graft failures was low and in the range of that obtained with other conditioning regimens. 34, 35, 38, 39 Cyclosporine A was the only immunosuppressive GVHD prophylaxis given after transplantation. This practice did not result in a higher frequency of aGVHD (14% Grades III + IV) than has been reported with other combinations, which frequently are associated with
Grade III and IV GVHD in more than 15% of patients. 1, 7, 34, 35 The rate of cGVHD (8% limited and 31% extensive) was likewise low. 1, 7, 35, 41 The comparison of the survival rates of patients treated with different reducedintensity conditioning regimens is difficult because disease status at transplantation and the heterogeneity of patient populations differ considerably among studies. The Kaplan-Meier estimates for overall survival of 73% and event-free survival of 49% in the present series encourage further evaluation of the treosulfan-containing regimen. Reduction of immunosuppression or DLI (with additional chemotherapy in one patient with refractory CLL) cured an additional proportion of the patients who relapsed or had persistent disease after transplantation and resulted in an estimated 63% probability of continuing CR after a median follow-up of 22 months.
In the context of the new conditioning approaches ranging from very light protocols ("mini-transplantation") to those with only attenuated-intensity combination chemotherapy derived from existing conventional transplantation protocols, the treosulfan and fludarabine regimen has to be considered a more intensive conditioning approach. 40 Application of almost two thirds of the maximum tolerated dose (47 g/m² after single injection 11, 12, 42 ) over 3 days obviously induces sufficient myeloablation/stem cell toxicity. In combination with fludarabine, potent pretransplant immunosuppression is given to guarantee prompt engraftment and complete donor chimerism in nearly all patients. At the same time, the toxicity of this conditioning regimen has to be considered to be comparably low and the dreaded side effects of busulfan-or melphalan-based conditioning regimens such as VOD and pulmonary or cardiac toxicity have not been observed. Taking into account the low relapse rate even of patients in disease stages with high relapse risk, the conditioning with treosulfan and fludarabine may be considered a full-intensity but reduced-toxicity conditioning regimen.
On the basis of the experience with other autologous or allogeneic treosulfancontaining protocols, 11, 12, 42 a study to escalate the treosulfan dose to a total of 42 g/m² is being conducted to further increase the antineoplastic potential while maintaining the low toxicity profile. Considering the suitability of combining treosulfan with, e.g., cyclophosphamide, melphalan, or etoposide, 12, 42, 43 this may ultimately lead to new reducedtoxicity but full-intensity conditioning regimens. From the results reported here, promising antineoplastic activity may be anticipated in myelodysplastic syndrome, AML, multiple myeloma, and NHL. In vitro/in vivo data for multiple myeloma, chronic myeloid leukemia, and acute myeloid leukemia support the potential activity of treosulfan in these indications also. This study has already shown that treosulfan and fludarabine is a favorable combination for conditioning with respect to toxicity, achievement of complete donor chimerism, and low GVHD rate and with a low treatment-related mortality and relapse rate. Consequently, the overall and disease-free survival rates are promising in a poor-risk patient population. 
